Lexaria Bioscience (NASDAQ: LEXX) has announced that full enrollment has been reached and dosing continues on schedule with Human Pilot Study #7 (GLP-1-H26-7) evaluating two oral DehydraTECH-semaglutide (DHT-sema) compositions against Novo’s (NYSE: NVO) commercially available Wegovy tablets, over a 5-week duration.
According to Lexaria, the study is investigating three separate arms to assess safety and tolerability as well as PK properties that will compare SNAC-inclusive, DHT-sema compositions formulated in both tablet and capsule formats to commercially available Wegovy tablets.
The company’s patented drug delivery formulation is DehydraTECH. The study is exploring several new DehydraTECH enhancements not previously evaluated including: an oral tablet DHT-sema composition which will be used by Lexaria for the first time—versus only the capsule compositions administered in all previous DehydraTECH GLP-1 studies; and both the Lexaria DHT-sema tablet and capsule test articles will be formulated with SNAC, which will be the first time these formulations will be evaluated over a multi-dose, multi-week time period in humans.
